Vendor, Tucson, AZ
Nuvox Pharma, L.L.C.
UEI WHNYG96UDLJ8, CAGE 51P42
1 award and -$393,000 obligated between November 1, 2024 and August 28, 2025, 100% under full and open competition, against 1.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | -$393,000 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | -$393,000 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50123C00034Definitive Contract, November 1, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Research and Development - Aoi #19 for the Development of Novel Oxygen Therapeutic NAN02 for Covid19: ExtendNAICS 541714, PSC AN13 | -$393,000 |
- Places of performance
- Arizona
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 4 across 1 awards